Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
September 15 2020 - 4:56PM
Business Wire
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical
stage biotechnology company targeting the CD40L pathway to develop
potential treatments for organ or cell-based transplant, autoimmune
and neurodegenerative diseases, today announced that
David-Alexandre C. Gros, M.D., Chief Executive Officer, will
present a corporate overview to virtual audiences this week at the
H.C. Wainwright & Co. 22nd Annual Global Investment Conference
and at the Cantor Virtual Global Healthcare Conference.
Conferences Details
Event:
H.C. Wainwright 22nd Annual Global
Investment Conference (virtual)
Date:
Wednesday, September 16th
Time:
3:30 p.m. ET
Event:
Cantor Virtual Global Healthcare
Conference (virtual)
Date:
Thursday, September 17th
Time:
12:00 p.m. ET
Live webcasts of both presentations can be accessed by visiting
the “Events and Presentations” tab of the investor section of the
Novus website at
http://ir.novustherapeutics.com/events-and-presentations/events. A
replay of the webcasts will be archived for 30 days following the
conference.
About Novus Therapeutics
Novus Therapeutics, Inc. is a clinical stage biotechnology
company using its expertise in targeting the CD40L pathway to
develop potential treatments for people requiring an organ or
cell-based transplant, and for people with autoimmune and
neurodegenerative disease. Novus is headquartered in Irvine, Calif.
For more information, please visit the company’s website at
www.novustherapeutics.com. Follow Novus Therapeutics on social
media: @Novus_Thera and LinkedIn.
Forward-Looking Statements
This press release contains forward‐looking statements that
involves substantial risks and uncertainties. Any statements about
the company’s future expectations, plans and prospects, including
statements about its strategy, future operations, development of
its product candidates, and other statements containing the words
“believes,” “anticipates,” “plans,” “expects,” “estimates,”
“intends,” “predicts,” “projects,” “targets,” “looks forward,”
“could,” “may,” and similar expressions, constitute forward‐looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, although not all forward‐looking statements
include such identifying words. Forward‐looking statements include,
but are not limited to statements regarding: risks related to
market conditions; expectations regarding the timing for the
commencement of future clinical trials; expectations regarding the
success of clinical trials; the rate and degree of market
acceptance and clinical utility of the company’s products; the
company’s estimates regarding expenses and cash runway; and the
impact of the ongoing coronavirus pandemic. Actual results may
differ materially from those indicated by such forward‐looking
statements as a result of various factors. These risks and
uncertainties, as well as other risks and uncertainties that could
cause the company’s actual results to differ significantly from the
forward‐looking statements contained herein, are discussed in our
quarterly 10-Q, annual 10-K, and other filings with the SEC, which
can be found at www.sec.gov. Any forward‐looking statements
contained in this press release speak only as of the date hereof
and not of any future date, and the company expressly disclaims any
intent to update any forward‐looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200915006306/en/
Amanda Sellers asellers@vergescientific.com 301.332.5574
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
From Apr 2023 to Apr 2024